Raphael Pharmaceutical Inc

For the period ended Sep 30, 2024. Filed Nov 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 14, 2024

RAPHStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Interim Statements of Changes in Stockholders’ Equity

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)

Common stock · Additional paid-in · Accumulated · Total
Number · Amount · capital · deficit · equity
Balance as of January 1, 2024	18,502,918	$185		$7,392	$(7,310)	$267
Issuance of common stock and warrants	158,500	2		178	-	180
Issuance of common stock in exchange for services	40,000	(*	)	61	-	61
Net loss	-	-		-	(798)	(798)
Balance as of June 30, 2024	18,701,418	$187		$7,631	$(8,108)	$(290)
Net loss	-	-		-	(326)	(326)
Balance as of September 30, 2024	18,701,418	187		$7,631	$(8,434)	$(616)

(*)	Less than 1 thousand.

Common stock · Additional paid-in · Accumulated · Total
	Number	Amount	capital	deficit	equity
Balance as of January 1, 2023	15,624,040	$157	$5,975	$(6,026)	$106
Issuance of common stock and warrants	543,128	5	309	-	314
Issuance of common stock in exchange for services	201,000	2	198	-	200
Net loss	-	-	-	(681)	(681)
Balance as of June 30, 2023	16,368,168	$164	$6,482	$(6,707)	$(61)
Issuance of common stock and warrants	1,734,250	17	694	-	711
Net loss	-	-	-	(725)	(725)
Balance as of September 30, 2023	18,102,418	181	$7,176	$(7,432)	$(75)

-F-4-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.